Clearmind Medicine Inc.
CMND · Pharmaceutical Preparations · EDGAR filings ↗
Reference price $3.31 — last insider sale, 2026-06-16 (estimated from the dated SEC Form 4 price — not a live quote)
Grade
D47gen composite 13pct→47
Notable findings
- Going concern● Our financial statements contain an explanatory paragraph regarding substantial doubt about our ability to continue as a going concern
- Insider buyingInsider buying — 1 open-market buy(s) by 1 insider(s) (~$330,335, last 6mo) Form 4 ↗
- Trial readout soonUpcoming trial readout ~2026-12-31 — PHASE1/PHASE2 · Alcohol Use Disorder
Key metrics
Return on equity
-323.4%
Return on assets
-63.4%
Current ratio
1.2×
Tangible book value
$1M
Cash & investments
$4M
Insider transactions · last 6 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-16 | HRT FINANCIAL LP | Sell | 22K | $3.31 |
| 2026-06-15 | HRT FINANCIAL LP | Sell | 3.2K | $3.32 |
| 2026-06-12 | HRT FINANCIAL LP | Sell | 2.1K | $3.36 |
| 2026-06-11 | HRT FINANCIAL LP | Sell | 225K | $0.12 |
| 2026-06-10 | HRT FINANCIAL LP | Buy | 2.2M | $0.15 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05913752 ↗ | A First in Human Study of CMND-100 in Healthy and Alcohol Use Disorder (AUD) Subjects Alcohol Use Disorder | PHASE1/PHASE2 | Recruiting | 2026-12-31 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-01-20 | 2025-10-31 | 0001213900-26-005665 ↗ |
| 20-F | 2025-01-22 | 2024-10-31 | 0001213900-25-005490 ↗ |
| 20-F | 2024-01-29 | 2023-10-31 | 0001213900-24-007413 ↗ |
| 20-F | 2023-02-06 | 2022-10-31 | 0001213900-23-008056 ↗ |